The part of Parkinson's the pills don't fix
Anyone who has cared for someone with Parkinson's disease knows the frustrating ceiling of current treatment. Levodopa works wonders for tremor and stiffness in the early years, but it has never done much for the symptoms families often worry most about: unsteady gait, freezing, falls, and the slow-motion cognitive changes that creep in after a decade.
Scientists have spent years asking why. If Parkinson's is just a shortage of dopamine, why don't dopamine pills fix everything?
A new systematic review points at a suspect that has been hiding in plain sight: the tiny blood vessels that feed brain tissue.
Why now
The research team pulled together every published study they could find comparing brain MRIs of people with Parkinson's disease to MRIs of healthy adults the same age. After screening more than 13,000 records across six major databases, 46 studies made the cut — covering 3,817 people with Parkinson's and 2,593 healthy comparisons. Average age was about 67 in both groups, so age alone cannot explain the differences they found.
What they were looking for
They were not measuring dopamine or looking at the classic Parkinson's trademark, the substantia nigra. They were counting signs of cerebral small vessel disease, or CSVD — a cluster of tiny injuries the brain accumulates when its smallest blood vessels struggle. On an MRI, CSVD shows up as:
- White matter hyperintensities — bright patches that mark damaged nerve-insulating tissue
- Lacunes — pinhole-sized old strokes
- Cerebral microbleeds — dots of leaked blood
- Enlarged perivascular spaces — widened fluid channels around small arteries
Think of it as rust on the brain's plumbing. Most adults pick up a little as they age; people with uncontrolled blood pressure or diabetes pick up more.
The main finding
People with Parkinson's carried more white-matter damage than healthy peers. The effect size was moderate — not dramatic, but consistent across the 21 studies that measured it by volume and the 14 that scored it visually. The pattern showed up in both the deep and periventricular regions of the brain.
The review also found a striking signal in one specific area: enlarged fluid channels around blood vessels in the midbrain. That is not a random location. The midbrain is home to the substantia nigra, the exact structure that dies back in Parkinson's. Enlarged channels there hint that the neighborhood around dying dopamine neurons is under vascular stress too.
What they did not find
Microbleeds and lacunes were not significantly more common in Parkinson's. That is worth knowing. The vascular story here is specifically about the slow, diffuse kind of small-vessel damage — not bigger stroke-like events.
Re-engaging with what it means
Why does this matter for a family sitting in a neurologist's office? Because if blood vessel health plays a role in Parkinson's progression, then the cardiovascular basics suddenly matter more than they used to: blood pressure control, cholesterol, diabetes management, exercise, sleep quality, and not smoking.
None of that replaces Parkinson's medication. But for symptoms that levodopa never fully helped — gait, falls, certain cognitive slowdowns — protecting small vessels may be the lever that is still available to pull.
What the experts are saying
Neurologists who study Parkinson's have long debated whether the disease is purely a neurodegenerative disorder or whether vascular factors pile on. This review lands firmly in the "both" camp. It does not prove that vascular damage causes Parkinson's. It shows the two travel together, and more often than chance would predict.
If you or someone you love has Parkinson's, a few practical implications flow from this work:
- Ask about vascular risk at your next visit. Blood pressure, A1C, cholesterol — the standard heart-health numbers are also brain-health numbers.
- Walking and aerobic exercise pull double duty. They help Parkinson's symptoms directly and also protect small blood vessels.
- An MRI finding of white-matter disease is not a second diagnosis — it is a related finding that may explain symptoms that Parkinson's meds have not touched.
The limitations worth naming
The authors themselves rate the evidence quality as low. Forty-five of the 46 studies were cross-sectional, meaning they looked at brains at a single moment rather than tracking how vascular damage unfolds over years. The pooled effect sizes are suggestive but not definitive, and heterogeneity between studies was substantial.
We also cannot tell from this review whether vascular damage came first, Parkinson's came first, or both share upstream causes like inflammation.
The next move is obvious but slow: long-term studies that MRI people every couple of years, starting before Parkinson's symptoms begin, and track how small vessel injury evolves alongside motor and cognitive decline. Standardized imaging protocols would also let researchers finally answer whether treating vascular risk aggressively changes the Parkinson's trajectory.
